Streetbeat News

GNNSF

Genscript Biotech Corporation

https://www.genscript.com

CEO

Fangliang Zhang

Industry

Testing Laboratories

Open

1.45

Mkt cap

2.9B

Volume

1.9K

High

1.45

P/E Ratio

-17.37

52-wk high

3.20

Low

1.39

Div yield

N/A

52-wk low

1.05

GenScript Biotech Corporation has announced the establishment of a new operations site and logistics center in Sydney, Australia, enhancing its global presence in life sciences services and products.

Portfolio Pulse from

November 11, 2024 | 3:00 am

Genscript Biotech Corp. (OTC:GNNSF) is considering selling its 48% stake in Legend Biotech (NASDAQ:LEGN) amid potential buyout offers. Legend's core cancer therapy, Carvykti, is expected to peak at $7.3 billion in annual sales. Despite Genscript's strong cash reserves, U.S. policy risks may influence its decision.

Portfolio Pulse from The Bamboo Works

August 01, 2024 | 2:52 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.